Comparative Pharmacology
Head-to-head clinical analysis: DARVON W ASA versus PAPA DEINE 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON W ASA versus PAPA DEINE 4.
DARVON W/ ASA vs PAPA-DEINE #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination analgesic: propoxyphene is a weak opioid agonist binding to mu-opioid receptors, inhibiting ascending pain pathways; aspirin irreversibly inhibits cyclooxygenase-1 and -2, reducing prostaglandin synthesis.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
1 capsule (propoxyphene HCl 65 mg / aspirin 650 mg) orally every 4 hours as needed for pain, not to exceed 6 capsules per day.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
None Documented
None Documented
Propoxyphene terminal half-life is 6–12 hours (mean 8 h) in healthy adults; prolonged in hepatic impairment or elderly due to reduced metabolism. Aspirin half-life is 15–20 minutes due to rapid hydrolysis to salicylate.
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
Renal elimination of propoxyphene and its metabolites accounts for ~70% of a dose, with ~20% excreted unchanged in urine; biliary/fecal elimination accounts for ~10%; aspirin is renally excreted as salicylate and its conjugates.
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination